PolandPoland

Bioton takes on insulin giants

01.03.2012

Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman Ryszard Krauze and Actavis CEO Claudio Albrecht announced that their companies have formed a joint venture for the development and registration of recombinantly produced insulins. While Bioton will develop and produce the insulins, the fourth largest generics producer will sell them in all EU countries, the US, Japan, Switzerland, Norway, Albania, Bosnia & Herzegovina, Croatia, Iceland, Kosovo, Liechtenstein, Montenegro and Macedonia. In Poland, both companies will market the products under their repective brands.

Facing off with the big boys

Under the terms of the agreement, Bioton will receive €22.25m upfront and a further €33.25m in milestones. Both companies expect revenues to reach €1.5bn in the seven years following the market launches of Bioton’s human recombinant insulin, short-acting insulins and long-acting insulins, the first step of which will commence at the end of 2012. The companies will share profits on a 50/50 basis. Actavis also secured an option to market Bioton’s insulins in 24 further markets, paying the Polish bioech firm €1m up front and €0.9m in milestone payments for the privilege.
For Bioton, which is the fourth firm globally to manufacture a human recombinant insulin (“gensulin”), the deal is a unique opportunity for expansion into the global market, which is currently dominated by three big players: Danish Novo Nordisk, French Sanofi and US pharma giant Eli Lilly. “For Bioton, the collaboration with Actavis will fuel faster expansion into high-margin markets,” commented the firm’s CEO Slawomir Ziegert. Albrecht said the deal involved more than just the sale of insulins and insulin analogues. “We are encountering competitor giants when it comes to insulin, and we have to maximise the competitive advantage that we clearly have.”
Bioton wants to be the first company on the market to offer biosimilar versions of recombinantly-produced human insulins, which will be much cheaper than IP-protected originator products. But Pfizer and its Indian manufacturing partner Biocon are hard on the heels of the Polish. Some insulins – such as Lilly’s Humulin, Novo Nordisk’s Novalin or Sanofi’s Lantus – have already lost patent protection. Others, like Levemir (Novo Nordisk) or the fast-acting insulins Humalog (Eli Lilly) and Novalog (Novo Nordisk) will follow in the next two years.
But Actavis also has plans beyond insulin. Albrecht announced the firm intends to launch a biosimilar for bestselling drugs every month during the first eight months of 2012. Bioton can benefit from the generics expert’s plans. Together with the initial announcement of the diabetes pact, which dates back to November 2010, Actavis said it will carry out a due diligence to acquire a 51% stake in Bioton’s Swiss subsidiary Biopartners – a biosimilar specialist.

PolandPoland

21.02.2009

Kraków – According to a report from Kraków-based PMR Ltd, the Czech Republic and Poland are on top in eastern Europe when it comes to outsourcing clinical trials and contract manufacture. The market analysis outlines 160...

PolandPoland

21.02.2009

Szczecin – The West-Pomeranian Center for Advanced Technologies and the German regional cluster BioCon Valley are setting up a German-Polish contact point for the life sciences. The long-term goal of the cooperation, which will...

PolandPoland

21.02.2009

Raszyn Rybie – Polish Euroimplant S.A. has received a66,000 in funding from the National Center for Research and Development (NCBiR) for product development, according to CE.biotech.com. The specialist firm for tissue...

PolandPoland

21.02.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its mana­gement board after announcing that an expected deal failed to materialise. In mid-January, after Prokom Investments (Gdynia) proved unable to sell...

PolandPoland

21.02.2009

Kraków – BioCentrum Sp. zo.o. is expanding contract research activities for the bio-pharmaceutical industry. In December, the Polish specialist for preclinical ADME, cell-based assays, protein characterisation, antibody, enzyme...

PolandPoland

23.01.2009

Warsaw – Polish insulin and antibiotics maker Bioton S.A. has shuffled its management board after a failed deal hit the news. When Prokom Investments (Gdynia) failed to sell a 33.3% stake in Bioton to Jerzy Starak’s Polpharma for...

PolandPoland

11.11.2008

Warsaw – In August, the lower chamber of the Polish parliament approved a 31m EUR programme for the protection of mental health to run from 2009-2013. The programme, which is to be financed from the state budget and EU funds,...

PolandPoland

18.08.2008

Portoroz – Around 120 international bioprocessing experts met at the 3rd Monolith Summer Symposium at Portoroz to discuss how monolith chromatography can eliminate current bottlenecks in downstream processing of biological drugs....

PolandPoland

20.05.2008

Krakow – Selvita Sp. z o.o., a newly founded service provider to the biotechnological and pharmaceutical industries, has taken over biotech tools and services supplier BioCentrum Ltd. At the end of March, Selvita acquired 64% of...

PolandPoland

20.05.2008

Warsaw – Together with the top ten Polish universities, one hundred Polish technology companies have kicked-off a business chamber for advanced technology (PIGZT). The chamber will provide a platform for improving information...

Displaying results 31 to 40 out of 108

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/3/article/bioton-takes-on-insulin-giants.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.81 EUR37.3%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • DIAGENIC (N)0.77 NOK-38.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6331.2%
  • IXICO (UK)66.50 GBP734.4%
  • PLETHORA (UK)10.00 GBP614.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.96 CHF-71.0%

No liability assumed, Date: 24.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper